Spironolactone and Insulin Resistance in Chronic Heart Failure (CHF)

Effects of Spironolactone on Insulin Resistance in Patients With Chronic Heart Failure

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00664222

Enrollment

Registered

2008-04-22

Start date

2004-01-31

Completion date

2005-12-31

Last updated

2008-04-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Stable Heart Failure

Keywords

heart failure, insulin resistance, inflammatory cytokine, spironolactone, furosemide

Brief summary

The purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Detailed description

Diuretics is useful in CHF patients. On the other hand, they deteriorate glucose metabolism. Therefore, the purpose of this study is to evaluate the effects of spironolactone and furosemide on insulin resistance in patients with chronic heart failure.

Interventions

DRUGspironolactone + furosemide

spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Inclusion criteria

* chronic stable heart failure

Exclusion criteria

* renal dysfunction or under treatment with antidiabetic agents

Design outcomes

Primary

Measure	Time frame
insulin resistance	16 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026